Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 557 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL August 7, 2020 COVID-19 Vaccines May Be Less Effective in Some People with Cancer May 26, 2021 Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... October 30, 2024 ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... July 1, 2025 Load more HOT NEWS Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... Reunión anual de la American Society of Clinical Oncology de 2023:... Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... Is there a right way to check your body for cancer?
